Amphastar Pharmaceuticals Inc. Company Profile
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Amphastar Pharmaceuticals at a glance
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Rancho Cucamonga, CA. Amphastar Pharmaceuticals is led by Dr. Yongfeng Zhang Ph.D. and employs about 1,976 people. The company's shares have traded publicly since 2014.
At a market capitalization of $1.20 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001297184, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Amphastar Pharmaceuticals do?
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Business description based on the company's public filings.
Company information
- Legal name
- Amphastar Pharmaceuticals Inc.
- Ticker
- NASDAQ: AMPH
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yongfeng Zhang Ph.D.
- Employees
- 1,976
- Headquarters
- 11570 6th Street, Rancho Cucamonga, CA, United States
- Phone
- 909 980 9484
- Website
- amphastar.com
- IPO year
- 2014
- Market cap
- $1.20B
- SEC CIK
- 0001297184
- Latest annual report
- 10-K · Feb 26, 2026
Companies similar to Amphastar Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs AMPH |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs AMPH |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs AMPH |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs AMPH |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs AMPH |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs AMPH |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs AMPH |
| GPCRStructure Therapeutics Inc. ADR | 16.13 | -5.78% | $1.15B | vs AMPH |